Baxter International (NYSE:BAX) Releases FY 2025 Earnings Guidance

Baxter International (NYSE:BAX) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 2.450-2.550 for the period, compared to the consensus estimate of 2.460. The company issued revenue guidance of $11.2 billion-$11.3 billion, compared to the consensus revenue estimate of $11.2 billion. Baxter International also updated its Q1 2025 guidance to 0.470-0.500 EPS.

Baxter International Price Performance

Shares of NYSE BAX opened at $33.87 on Friday. The stock’s 50-day simple moving average is $30.65 and its 200-day simple moving average is $34.14. The firm has a market capitalization of $17.29 billion, a PE ratio of -26.46, a price-to-earnings-growth ratio of 10.62 and a beta of 0.61. Baxter International has a fifty-two week low of $28.33 and a fifty-two week high of $44.01. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, topping the consensus estimate of $0.52 by $0.06. The firm had revenue of $2.75 billion for the quarter, compared to analyst estimates of $2.67 billion. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. As a group, equities research analysts forecast that Baxter International will post 2.48 EPS for the current fiscal year.

Baxter International Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be paid a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 2.01%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International’s payout ratio is currently -53.13%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Stifel Nicolaus dropped their price target on Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Barclays assumed coverage on shares of Baxter International in a research report on Thursday. They set an “overweight” rating and a $39.00 target price for the company. JPMorgan Chase & Co. cut their price objective on Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Friday. StockNews.com cut Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. Finally, Citigroup reduced their price objective on Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $38.80.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.